Previous 10 | Next 10 |
SILVER SPRING, Md. , April 29, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that its collaborator, XVIVO Perfusion, Inc., a subsidiary of XVIVO Perfusion AB (STO: XVIVO), has received Premarket Approval (PMA) from the U.S. Food and Drug Administratio...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , April 24, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2019 financial results before the market opens on Wednesday, May 1, 2019 . United Therapeutic...
United Therapeutics (NASDAQ: UTHR ) is "disappointed" with a just-filed lawsuit filed by Sandoz and RareGen, LLC claiming the company engaged in anticompetitive behavior aimed at blocking their launch of generic Remodulin (treprostinil). More news on: United Therapeutics Corporation...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , April 17, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) was named as a defendant, along with Smiths Medical ASD, Inc., in a lawsuit filed in federal court by Sandoz Inc. and RareGen, LLC on April 16, 2019 . ...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , April 8, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that the BEAT clinical study of esuberaprost tablets in patients suffering from pulmonary arterial hypertension did not meet its primar...
MannKind's ( MNKD ) investors saw a nice pop in scripts with the last week of the quarter. The pop came in the refill line, while new scripts continue to move along at a modest pace. At this stage, the refill number is an anomaly. While those passionate about the company want it to be the new ...
MannKind ( MNKD ) investors have had an interesting weekend. On Friday, March 29, 2019, the company filed (after-hours) a $500 million shelf registration . This was followed by a pre-market announcement on April 1, 2019 that the company was in receipt of a $12.5 million milestone payment fro...
MannKind Corporation (NASDAQ: MNKD ) has achieved the first of several milestones under its licensing and collaboration agreement with United Therapeutics (NASDAQ: UTHR ) for the development and commercialization of a dry powder formulation of treprostinil. More news on: MannKind Corpora...
Novartis (NYSE: NVS ) unit Sandoz announces the U.S. commercial launch of its generic version of United Therapeutics' (NASDAQ: UTHR ) PAH med Remodulin (treprostinil). More news on: Novartis AG, United Therapeutics Corporation, Healthcare stocks news, Read more ...
The following slide deck was published by United Therapeutics Corporation in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...